Research Triangle Park,
This is a retrospective cohort study of children included in a large medical insurance
- To evaluate the rate of FluMist administration compared to other influenza vaccine use
in the following pediatric populations:
- Children younger than 24 months of age
- Children 24-59 months of age with a claim associated with a diagnosis of asthma
- Children 24-59 months of age without a claim associated with a diagnosis of
asthma, but with dispensed medication for wheezing
- Children 24-59 months of age with immunosuppression
- To describe, in children in the above populations who receive FluMist, the type and
number of Emergency Room visits or hospitalizations associated with an insurance claim
within 42 days of receiving FluMist
- To explore the rationale for FluMist immunization of pediatric populations that are
excluded from recommended usage by characterizing the use in these populations
- Children less than 24 months of age during August through January/February.
- Children <24 to 59 months of age during August through January/February, with:
- two outpatient claims for asthma, or
- one inpatient/emergency room claim for asthma, or
- one outpatient claim for asthma and at least one SABA prescription during a
defined 12-month period.
- Children <24 to 59 months of age during August through January/February, without any
claims associated with a diagnosis of asthma, but with at least one dispensing for
SABA, as indicated by pharmacy claims during a defined 12-month period.
- Children 24 to 59 months of age during August to January/February with evidence of
immunosuppression prior to the date of influenza vaccination based on available
medical and pharmacy claims.